Advertisement

Langzeitkonsequenzen der intrauterinen Drogenexposition

  • Ludwig Gortner

Zusammenfassung

Die intrauterine Drogenexposition hat neben der potenziellen primären Schädigung für die Schwangere auch tiefgreifende kurz- und langfristige Konsequenzen für das Neugeborene. Hierbei sind zunächst die unmittelbaren Konsequenzen in Form des neonatalen Drogenentzugssyndroms zu berücksichtigen, die nach Daten aus den USA [26] in ihrer Häufi gkeit zwischen 2000 und 2009 um den Faktor 3,5 angestiegen sind: War es im Jahre 2000 etwa eines von 1000 Neugeborenen, das stationär in neonatologischen Stationen betreuungsbedürftig war, stieg die Anzahl auf knapp 3,5 im Jahre 2009 an. Die daraus resultierenden, berechneten Behandlungskosten waren parallel um den Faktor von rund 1,5 im Mittel pro Patient gestiegen. Die direkten Behandlungskosten pro Patient und Aufenthalt lagen im Jahr 2000 bei ca. 6600,– US$ und stiegen bis 2006 auf 9600,– US$ an [26].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ackerman JP, Riggins T, Black MM. A review of the effects of prenatal cocaine exposure among school-aged children. Pediatrics 2010; 125: 554–565.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Aiken CE, Ozanne SE. Sex differences in developmental programming models. Reproduction 2013; 145: R1–13.CrossRefGoogle Scholar
  3. 3.
    Andrade C. Use of acetaminophen (paracetamol) during pregnancy and the risk of attention-deficit/hyperactivity disorder in the offspring. J Clin Psychiatry 2016; 77: e312–314.Google Scholar
  4. 4.
    Bada HS, Bann CM, Whitaker TM et al. Protective factors can mitigate behavior problems after prenatal cocaine and other drug exposures. Pediatrics 2012; 130: e1479–1488.Google Scholar
  5. 5.
    Bayley N. Bayley Scales of Infant and Development Manual. In: The Psychological Corporation. 2nd ed. San Antonio, TX: Harcourt Brace & Company, 1993.Google Scholar
  6. 6.
    Behnke M, Eyler FD, Warner TD et al. Outcome from a prospective, longitudinal study of prenatal cocaine use: preschool development at 3 years of age. J Pediatr Psychol 2006; 31: 41–49.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Betancourt LM, Yang W, Brodsky NL et al. Adolescents with and without gestational cocaine exposure: Longitudinal analysis of inhibitory control, memory and receptive language. Neurotoxicol Teratol 2011; 33: 36–46.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chaplin TM, Visconti KJ, Molfese PJ et al. Prenatal cocaine exposure differentially affects stress responses in girls and boys: associations with future substance use. Dev Psychopathol 2015; 27: 163–180.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chiriboga CA, Kuhn L, Wasserman GA. Neurobehavioral and developmental traiectories associated with level of prenatal cocaine exposure. J Neurol Psychol 2014; 2: 12.Google Scholar
  10. 10.
    Fang SY, Huang N, Lin T et al. Health insurance coverage and healthcare utilization among infants of mothers in the national methadone maintenance treatment program in Taiwan. Drug Alcohol Depend 2015; 153: 86–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Gentile S. Prenatal antidepressant exposure and the risk of autism spectrum disorders in children. Are we looking at the fall of Gods? J Affect Disord 2015; 182: 132–137.CrossRefPubMedGoogle Scholar
  12. 12.
    Gray KA, Day NL, Leech S et al. Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol 2005; 27: 439–448.CrossRefPubMedGoogle Scholar
  13. 13.
    Hall ES, Isemann BT, Wexelblatt SL et al. A cohort comparison of buprenorphine versus methadone treatment for neonatal abstinence syndrome. J Pediatr 2016; 170: 39–44 e31.CrossRefPubMedGoogle Scholar
  14. 14.
    Hoover RM, Hayes VA, Erramouspe J. Association between prenatal acetaminophen exposure and future risk of attention deficit/hyperactivity disorder in children. Ann Pharmacother 2015; 49: 1357–1361.CrossRefPubMedGoogle Scholar
  15. 15.
    Hurd YL, Wang X, Anderson V et al. Marijuana impairs growth in mid-gestation fetuses. Neurotoxicol Teratol 2005; 27: 221–229.CrossRefPubMedGoogle Scholar
  16. 16.
    Jacobson SW, Chiodo LM, Sokol RJ et al. Validity of maternal report of prenatal alcohol, cocaine, and smoking in relation to neurobehavioral outcome. Pediatrics 2002; 109: 815–825.CrossRefPubMedGoogle Scholar
  17. 17.
    Jaeger DA, Suchan B, Scholmerich A et al. Attention functioning in children with prenatal drug exposure. Infant Ment Health J 2015; 36: 522–530.CrossRefPubMedGoogle Scholar
  18. 18.
    Kandall SR, Albin S, Lowinson J et al. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976; 58: 681–685.Google Scholar
  19. 19.
    Konijnenberg C, Melinder A. Executive function in preschool children prenatally exposed to methadone or buprenorphine. Child Neuropsychol 2015; 21: 570–585.CrossRefPubMedGoogle Scholar
  20. 20.
    LaGasse LL, Derauf C, Smith LM et al. Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics 2012; 129: 681–688.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Logan BK. Methamphetamine – effects on human performance and behavior. Forensic Sci Rev 2002; 14: 133–151.Google Scholar
  22. 22.
    Messinger DS, Bauer CR, Das A et al. The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics 2004; 113: 1677–1685.CrossRefPubMedGoogle Scholar
  23. 23.
    Minozzi S, Amato L, Bellisario C et al. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013; 12: CD006318.Google Scholar
  24. 24.
    Nulman I, Rovet J, Altmann D et al. Neurodevelopment of adopted children exposed in utero to cocaine. CMAJ 1994; 151: 1591–1597.Google Scholar
  25. 25.
    Ornoy A, Daka L, Goldzweig G et al. Neurodevelopmental and psychological assessment of adolescents born to drug-addicted parents: effects of SES and adoption. Child Abuse Negl 2010; 34: 354–368.CrossRefGoogle Scholar
  26. 26.
    Patrick SW, Schumacher RE, Benneyworth BD et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA 2012; 307: 1934–1940.Google Scholar
  27. 27.
    Rhodes T, Bernays S, Houmoller K. Parents who use drugs: accounting for damage and its limitation. Soc Sci Med 2010; 71: 1489–1497.CrossRefGoogle Scholar
  28. 28.
    Richardson GA, Ryan C, Willford J et al. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol 2002; 24: 309–320.CrossRefPubMedGoogle Scholar
  29. 29.
    Sarfi M, Sundet JM, Waal H. Maternal stress and behavioral adaptation in methadone- or buprenorphine-exposed toddlers. Infant Behav Dev 2013; 36: 707–716.CrossRefPubMedGoogle Scholar
  30. 30.
    Steinhausen HC, Blattmann B, Pfund F. Developmental outcome in children with intrauterine exposure to substances. Eur Addict Res 2007; 13: 94–100.CrossRefPubMedGoogle Scholar
  31. 31.
    Tolia VN, Patrick SW, Bennett MM et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015; 372: 2118–2126.CrossRefPubMedGoogle Scholar
  32. 32.
    Webster WS, Abela D. The effect of hypoxia in development. Birth Defects Res C Embryo Today 2007; 81: 215–228.CrossRefGoogle Scholar
  33. 33.
    Webster WS, Brown-Woodman PD. Cocaine as a cause of congenital malformations of vascular origin: experimental evidence in the rat. Teratology 1990; 41: 689–697.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  • Ludwig Gortner
    • 1
  1. 1.Klinik für Kinder- und JugendheilkundeMedizinische Universität WienWienAustria

Personalised recommendations